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Alemtuzumab in Allogeneic Sibling or Unrelated Donor
Hematopoetic Cell Transplantation: The Feasibility
of Deescalation
Hartmut Bertz, Alexandros Spyridonidis, Ralph Wa¨sch, Carsten Gru¨llich,
Mathias Egger, Ju¨rgen FinkeProphylaxis of acute graft-versus-host disease (aGVHD), while maintaining the graft-versus-leukemia (GVL)/
lymphoma effect and preventing severe infectious diseases, remains the main challenge in allogeneic hema-
topoetic cell transplantation (allo-HCT). To evaluate this, we examined the feasibility of deescalating the dose
of alemtuzumab (MabCampath) in combination with cyclosporine (CsA) as the sole GVHD-prophylaxis in
patients after fludarabine (Flu)-based reduced-intensity conditioning (RIC) in an observational cohort study.
We included 127 consecutive patients (median age 63 years) with an unrelated (UD; n569) or related donor
(SIB; n558) after their first transplantation, mostly presenting with advanced disease. The first 30 patients
received 20mg/day on day22 and21 (40mg), the following 48 patients 10mg/day on day22 and21 (20mg),
and the last 49 patients 10 mg on day 2 1 (10 mg) alemtuzumab intravenous (i.v.) prior to transplant. We
observed no statistical differences comparing the 40 mg, 20 mg, or 10 mg dose groups, in terms of cumulative
incidences of aGVHD grade III-IV 7% (confidence interval [CI] 95%; 1-51), 12% (1-40), 6% (1-40), extensive
chronic GVHD (cGVHD) 24.4% (3.3-55.8), 17% (2.5-42), and 14.2% (1.5-41.5) and of aGVHD grade II-IV 7 %
(0-51.5), 29% (11.9-49.1), 21% (15.3-43.1), respectively. The difference between the 20-mg and 40-mg groups
was significant for aGVHD grade II-IV(P\.05). In conclusion, we demonstrate the feasibility of reducing the
dose of alemtuzumab as GVHD-prophylaxis to 10 mg absolute in combination with CsA only for UD trans-
plantation in particular.
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To reduce the incidence and severity of acute
graft-versus-host disease (aGVHD), especially in vol-
unteer unrelated donor transplantation (UD), poly-
clonal antibodies like antithymocyte globulin (ATG)
have been used in combination with standard cyclo-
sporine/methotrexate (CsA/MTX) prophylaxis [1].Albert Ludwigs-University Medical Center Freiburg,
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6/j.bbmt.2009.08.002A group of monoclonal antibodies (mAbs) against
CD52 (Campath-1) were introduced [2] to deplete
recipient and donor T cells, provide engraftment,
and prevent severe aGVHD. The anti-CD52 antibody
was initially used for in vitro T cell depletion by expos-
ing stem cell products to the rat Campath-1 G, a pro-
cedure called ‘‘Campath in the bag’’ [3]. Campath-1H
(alemtuzumab) is a humanized IgG 1 mAb that recog-
nizes the CD52 antigen on human lymphocytes, natu-
ral killer (NK) cells, monocytes/macrophages,
dendritic cells, and eosinophils, but not on hemato-
poetic stem cells (HSCs) [4,5]. Campath-1H has
been studied in vitro [6] and used in vivo as part of con-
ditioning regimens since 1997 [7].
Initially, the total dose of alemtuzumab was 100
mg total dose given i.v. over 5 days prior to transplan-
tation [2,7]. Although panlymphocyte depletion
resulted in significantly less GVHD, there was in-
creased incidence of severe viral and opportunistic
infections, graft failure, and relapse. To prevent these
complications, 2 groups reduced the alemtuzumab
dose as part of the conditioning regimen to 50 mg total1563
Table 1. Patients, Transplantation, and Donor Characteristics
Alemtuzumab dose
40 mg
(n530)
20 mg
(n548)
10 mg
(n549)
Time period of HCT 2003-2005 2005-2006 2006-2007
Age in median 61.4 y (39-71) 64.8 y (30-75) 63.7 y (24-76)
Diagnosis n (%) n (%) n (%)
De novo AML 6 (20) 9 (19) 20 (41)
t,s,ts AML/MDS,MDS 5 (17) 22 (46) 23 (47)
NHL, HL, MM, CLL 15 (50) 10 (21) 2 (4)
ALL 0 5 (10) 2 (4)
CML/MPS 4 (13) 2 (4) 2 (4)
Remission at HCT
CR1/CP1 5 (17) 8 (17) 5 (10)
Untreated 5 (17) 15 (31) 10 (20)
advanced
(PIF, REL, PROG, >CR1) 20 (66) 25 (52) 34 (70)
Conditioning regimens
Flu/B/Mel 29 (97) 44 (92) 45 (92)
Flu/TT 1 (3)
Flu/B/TT 4 (8) 4 (8)
Donor characteristics
Male: female 15:15 32:16 27:22
Sibling:UD 24:6 14:34 20:29
BM: PBSC 1:29 2:46 0:49
HLA mismatch >1 1 (3) 2 (4) 0
A, B, C 2 (7) 12 (25) 8 (16)
DRB1, DQB1 1 (3) 2 (4) 1 (3)
CMV serology
D +/ P2 4 (13) 4 (8) 8 (16)
D2/ P + 10 (34) 10 (21) 11 (22)
D +/ P + 12 (40) 26 (54) 18 (37)
D2/ P2 4 (13) 8 (16) 12 (25)
G-CSF post-TX 8 (27) 0 0
y indicates years; AML, acute myelogenous leukemia; MDS, myelodys-
plastic syndrome; tAML, therapy-associated AML; sAML, secondary
AML; tsAML, therapy-associated secondary AML; MDS, myelodysplastic
syndrome; MPS, myeloproliferative syndrome; NHL non-Hodgkin lym-
phoma; CLL, chronic lymphocytic lymphoma; MM, multiple myeloma;
HCT, hematopoetic cell transplantation; CR, complete remission; CP,
chronic phase; REL, relapse; PIF, persistant induction failure; other,
chronic phase, accelerated phase, blast crisis, progression, partial remis-
sion, stable disease; TX, transplantation; allo, allogen; auto, autologous;
UD, unrelated donor; CMV, cytomegalovirus; D, donor; P, patient;
G-CSF, granulocyte colony-stimulating factor; Flu, fludarabine; B, car-
mustin; Mel, melphalan; TT, thiotepa.
1564 Biol Blood Marrow Transplant 15:1563-1570, 2009H. Bertz et al.dose in sibling and UD transplantation [8,9] in addi-
tion to using calcineurin inhibitors and MTX as
GVHD prophylaxis.
In an effort to reduce infectious complications and
maintain a significant graft- versus-malignancy effect,
we aimed at further reducing the total dose of alemtu-
zumab dose and substituting MTX and mycophenolat-
mofetil (MMF), because of their side effects as part of
the GVHD prophylaxis in our reduced-intensity con-
ditioning (RIC) protocols [10-12]. The observational
design was to initially use alemtuzumab 40 mg total
dose and deescalate to 20 mg total if aGVHD and
mortality rates did not increase in 70 patients com-
pared to our standard GVHD prophylaxis used before,
consisting of CsA/MMF or CsA/MTX. Further alem-
tuzumab tapering (10 mg total) was dependent on the
noninferiority of 20 mg to 40 mg after interim analysis
of significant numbers of patients treated. Therefore,
in 2002, we incorporated lower doses of alemtuzumab
(total 40 mg) as part of our GVHD prophylaxis in
combination with CsA into our internal review board
(IRB) and ethics committee-approved RIC protocol
designed for relapsed patients undergoing second allo-
geneic transplantation [10], and since 2003, included it
in our primary RIC-protocol study protocol [11,12].
As we did not observe higher incidences of aGVHD
and morbidity, we further amended the protocol to
deescalate the alemtuzumab dose to 20 mg total, and
later, a 10-mg total dose.
Here we report data from our observational study
with 3 consecutive patient cohorts after their first
transplantation receiving the i.v. administration of
3 doses of alemtuzumab (40 mg, 20 mg, and 10 mg)
in combination with CsA as GVHD prophylaxis.
Our experience in 127 consecutive patients with
hematologic malignancies who underwent UD
(n569) or sibling donor (n558) transplantation show
similar results for aGVHD and extensive chronic
GVHD (cGVHD).PATIENTS AND METHODS
Patient Characteristics
Patient characteristics are listed in Table 1. The 127
patients received their first transplantation for de novo
acute myelogenous leukemia (AML, n535), therapy-
related or secondary AML or myelodysplastic syndrome
(MDS0, refractory anemia (RA), refractory anemia with
excess blasts (RAEB) 2, refractory anemia with excess
blasts in transformation (RAEB-T), chronic myelomo-
nocytic leukemia (CMMoL) (n550), acute lymphoblas-
tic leukemia (ALL; n57), non-Hodgkin lymphoma
(NHL)/Hodgkin lymphoma (HL)/multiple myeloma
(MM)/chronic lymphocytic leukemia (CLL) (n527),
and chronic myelogenous leukemia (CML)/other mye-
loproliferative syndromes (MPS) (n58). The 53 femaleand 74 male patients had a median age of 63 years (24-76
years). At transplantation, 30 patients were untreated, 18
patients were in first complete remission or first chronic
phase (CR1/CP1), and all other patients (n579) had ad-
vanced disease (CR.1,.CP1, persistent induction fail-
ure, relapse $1, progressive disease, partial remission,
stable disease). One hundred three of the 127 patients
(81%) were at risk at transplantation for cytomegalovi-
rus (CMV) infection/disease because of positive pre-
transplant CMV serology in the patient and/or donor.
Conditioning Regimen, GVHD Prophylaxis, and
Stem Cell Source
All patients received fludarabine (Flu)-based RIC
regimens. Inclusion criteria have been published else-
where [10-12]. One hundred eighteen patients received
Flu (Schering, Berlin, Germany) 30 mg/m2/day given
from day29 to day25 (since July 2005: Flu 30 mg/m2
4 days from day 28 to day 25), carmustine (Bristol
Myers Squibb, Munich, Germany) 200 mg/m2/day
Biol Blood Marrow Transplant 15:1563-1570, 2009 1565Low-Dose Alemtuzumab as GVHD-Prophylaxis(\55 years of age) or 150 mg/m2/day ($55 years) given
from day 27 to day 26, and melphalan (Mel; Glaxo-
SmithKline, Hamburg, Germany) 140 mg/m2/day
(\55 years of age) or 110 mg/m2/day ($55 years) given
at day24, as previously described (Flu/B/Mel regimen;
n5118) [11,12]. One patient received Flu 30 mg/m2/
day given from day 27 to day 24 and thiotepa 5 mg/
kg/day for 3 days given from day 26 to day 24 (Flu
TT; n51) [10]. Seven patients with ALL, and 1 patient
with AML received Flu 330 mg/m2, BCNU 300 mg/
m2 and thiotepa 45 mg/kg (Flu/Blu/TT; n58).
The GVHD prophylaxis consisted of i.v. cyclo-
sporine A (CsA) starting at day –3 at a dose of 2.5
mg/kg twice a day (trough level 250-350 ng/mL)
[10-12] in combination with alemtuzumab (MabCam-
path, Schering, Berlin, Germany) given i.v. over 4
hours. In 2003, the alemtuzumab was given in a total
dose of 40 mg by infusing 20 mg/day on days 22 and
21 (n530, group 40 mg). Since July 2005, alemtuzu-
mab has been deescalated to a total dose of 20 mg given
as 10 mg/day on days22 and21 (n548, group 20 mg),
and, since June 2006, we have been giving a single dose
of 10 mg on day 21 (n549, group 10 mg) (Table 1).
Comedication included 100 mg prednisolone, 10 mg
clemastine (H1-blocker), and 50 mg ranitidin before
and directly after the alemtuzumab infusion. In the
case of adverse reactions we extended the usual infu-
sion time (2 hours) and administered additional corti-
costeroids. After transplantation, in patients without
GVHD, orally administered CsA was usually tapered
from day 160, and usually discontinued at day 1120.
The main graft source were (124/127 [98%])
unmanipulated rhu-granulocyte-colony stimulated
factor (G-CSF)-mobilized peripheral blood stem cells
(PBSCs), whereas bone marrow (BM) was transplanted
in 3 UD transplantations because of availability. Do-
nors were siblings (n558; 46%) and unrelated volun-
teers (n569; 54%). HLA class I antigens were typed
by serology or intermediate resolution DNA tech-
niques (2 digits) and HLA class II by high-resolution
DNA techniques (4 digits) [11]. The unrelated donors
were mismatched in HLA-A, -B, -C, -DRB1, or
DQB1 in 26/69 (38%) of the transplantations with
more than 1 mismatch in 3 patients (Table 1).Protocol History
All patients gave informed consent to being
included in a local IRB and ethics committee-approved
RIC protocol. The protocol was carried out according
to the Helsinki declaration. The GVHD prophylaxis
protocol containing alemtuzumab (220 mg) was
established initially within second transplantations
[10]. Because of the low incidence of aGVHD in these
patients, in 2003 first transplants from both sibling and
UD were included by amendment. After an interim
analysis for aGVHD rate and mortality of 71 patientsreceiving alemtuzumab 40 mg total dose in combina-
tion with CsA (data not shown), the alemtuzumab
dose was deescalated to 20 mg total by amendment
in 2005, and finally to 10 mg total in 2006 following in-
terim analysis of the 61 patients previously treated with
210 mg (data not shown), because of low morbidity
and a similarly low rate of aGVHD.
Supportive Care
Standard supportive care was given as previously
described [13]. Briefly, all patients received flucona-
zole and ciprofloxacin prophylaxis until day 125 and
acyclovir prophylaxis until day 1100. In the case of
fever, broad-spectrum antibiotic treatment was started
and escalated according to our in-house standards [11].
The first 8 patients included in the 40-mg group re-
ceived filgrastim (Amgen, Munich, Germany) at 5
mg/kg starting on day 17 and until leukocytes
.1109/L. After stable engraftment, cotrimoxazole
(TMS) was added twice per week (or an alternative
regimen consisting of dapsone/daraprime) for pneu-
mocystis jiroveci pneumonia (PjP) prophylaxis. CMV
in peripheral blood was monitored in all patients using
fluorescein antigen-detection methodology and by
quantitative CMV-polymerase chain reaction (PCR)
twice weekly after engraftment and up to discharge,
once weekly up to day 1100, and at least once every
3 weeks until immunnosuppression was completely
withdrawn and no GVHD was present. In cases of pos-
itive CMV antigenemia or 1 positive CMV-PCR with
copy numbers above 3000/mL or 2 consecutive positive
CMV-PCR assays.1000/mL, we initiated preemptive
standard ganciclovir, valganciclovir, or foscarnet
therapy for at least 1 week until the apparent CMV
negativity [1]. CMV infection was defined as asymp-
tomatic CMV antigenemia or PCR positivity in
peripheral blood requiring preemptive therapy; a posi-
tive culture in any histologic tissue was considered as
CMV disease [14,15]. Since 2003, we have monitored
Epstein-Barr virus (EBV) infection/reactivation in pe-
ripheral blood and by quantitative PCR, defining EBV
reactivation whenever copies were above 5000/mL.
EBV-associated disease/infection was defined as posi-
tive EBV-PCR in any nonblood specimen or as post-
transplantation lymphoproliferative disease (PTLD)
with additional new lymphomas on any side. Studies
for other viral (adenovirus, respiratorial syncytial virus,
varizella zoster virus) and PjP infections were per-
formed when indicated.
Study Endpoints, Definitions, and Statistical
Analysis
Data were evaluated as of December 31, 2008. Fol-
low-up of all patients was complete. aGVHD and
cGVHD was assessed using the criteria of Przepiorka
and Shulman [16,17]. The day of engraftment was
Table 2. Engraftment
40 mg (n530) 20 mg (n548) 10 mg (n549)
Engraftment
WBC (day +, range, n5evaluable patients)
>0.5109/L 11 (8-20) n529 12 (0-24) n546 12 (8-16) n548
> 1 x 109/L 12 (9-23) n529 14 (9-25) n546 13 (8-18) n548
ANC (median day +, range, n5evaluable patients)
> 0.5 x 109/L 13 (9-42) n529 17 (10-28) n546 15 (11-54) n548
>1109/L 16 (11-42) n529 18.5 (10-36) n545 17 (12-54) n548
Platelets (day +)
>20109 /L 10 (7-23) n528 11 (0-48) n543 11 (6-34) n548
>50109/L 12 (8-37) n527 14 (9-97) n542 13 (10-64) n546
WBC indicates total white blood cell; ANC, absolute neutrophil count.
1566 Biol Blood Marrow Transplant 15:1563-1570, 2009H. Bertz et al.defined as the first of 3 consecutive days with leuko-
cytes $1109/L. Platelet recovery was defined as
a platelet count $20109/L without transfusion.
The time to event was analyzed using the Kaplan-
Meier method and the different groups were compared
by the Log-Rank test and the 2-tailed t-test. This
included the estimated cumulative incidences of
aGVHD and cGVHD, leukocyte and platelet recov-
ery, incidence of CMV infection, of morphologic
relapse, overall survival (OS), and nonrelapse mortality
(NRM). Kaplan-Meier estimates were based on the
time from hematopoietic cell transplant (HCT) until
the censored event or death. All statistical analyses
were calculated using the commercially available
GraphPad PRISM Version 5.00.RESULTS
Engraftment
Engraftment occurred in 123/127 evaluable
patients leukocyte engraftment $1109/L occurred
at a median of 12 days (range: 9-24, n529) in the
40-mg group, by day 114 (range: 9-25, n546) in the
20-mg group, and by day 113 (range: 8-18, n548) in
the 10-mg group, with no statistical difference among
the 3 groups (Table 2). The absolute neutrophil count
(ANC) $1109/L revealed similar results: day 116
(range: 11-42, n529; group 40), day 118.5 (range:
10-36, n545; group 20 mg), and day 117 (range:
11-54, n548; group 10 mg).
Three patients died before stable engraftment in
the 20-mg (n52) and 40-mg groups (n51). Overall,
we observed only 1 primary graft failure in a female
patient from the 10-mg group with untreated MPS/
chronic neutrophilic leukemia in the accelerated
phase; stable engraftment was achieved by a second
transplantation from the same donor.
Stable platelet counts$20109/L were reached at
median day110 (range: 7-23, n528, group 40 mg) and
day 111 in both other groups (range: 0-48, n543,
group 20 mg; range: 6-34, n548, group 10 mg). Plate-
let counts $50109/L were reached by day 112
(range: 8-37; n527, group 40 mg), day 114 (range:
9-97, n542, group 20 mg; and day 113 (range:
10-64, n546; group 10 mg), respectively.
Three of 30 patients in group 40 mg, 6/48 in group
20 mg, and 3/49 in group 10 mg died prior to stable
platelet engraftment (Table 2).Acute GVHD
Of the 127 patients, 124 were evaluable for
aGVHD evaluation after engraftment. Clinically rele-
vant aGVHD grade II-IV developed with a cumulative
incidence of 7% (2/30) and grade III-IV of 7% (2/30)
in the 40-mg group. Acute GVHD grade II-IV ingroup 20 mg occurred with a cumulative incidence of
29% (13/48) and grade III-IV of 12% (5/48), and in
the 10-mg group with a cumulative incidence of 21%
grade II-IV (10/49) and grade III-IV of 6% (3/49), re-
spectively. There were no differences in the
occurrence of grade II-IV and III-IV aGVHD among
the 3 dose groups, except when comparing the 20-mg
and the 40-mg group for aGVHD grade II-IV(P\ .05)
(Figure 1).
The incidence of aGVHD within the 3 groups
according to the graft source (SIB versus UD) revealed
no significant difference for aGVHD grade II-IV and
grade III-IV in the unpaired t-test.
The results in detail: after 40 mg total dose of
alemtuzumab, aGVHD grade II-IV developed in
27% in UD transplantation compared to 0% (P \
.005) after sibling transplantation, and for aGVHD
grade III-IV 23.8% after UD and 0% (p5not signifi-
cant [n.s.]) in SIB transplantation (Figure 2). Within
the 20-mg group, there was a cumulative 34% inci-
dence of aGVHD grade II-IV after UD and 16%
(P5n.s.) after sibling transplantation. The comparison
for aGVHD grade III-IV (12.5% in UD and 7% in SIB
transplantations) is n.s.
Within the 10-mg group, UD resulted in a nonsig-
nificant higher incidence of grade II-IV aGVHD com-
pared to SIB transplantation (UD 28% versus SIB
10%; P5ns) but a similar occurence of severe grade
III-IV aGVHD (UD 7% versus SIB 5%; P5n.s.).
The cumulative incidence of severe aGVHD was not
higher after UD transplantation (Figure 2).Chronic GVHD
Of the 127 patients observed, 111 were evaluable
for cGVHD evaluation. No cGVHD developed in
14 patients of the 40-mg, 28 patients of the 20-mg
group, and 30 patients of the 10-mg group, respec-
tively. The cumulative incidence of cGVHD was
44% (40-mg group), 38% (20-mg group), and 37%
(10-mg group). The corresponding values for exten-
sive cGVHD are 24.4% (40-mg group) and 17%
(20-mg group) and 14.2% (10-mg group). Statistical
analysis revealed no significant differences (Figure 3).
Figure 1. Kaplan-Meier estimated incidences of aGVHD grade II-IV
and grade III-IV.
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Figure 2. (a,b) Kaplan-Meier estimated incidences of aGVHD grade II-
IV and grade III-IV in comparison with graft source (SIB/UD).
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CMV infections/reactivations requiring preemp-
tive therapy were detected in 38% (10/26), 55% (22/
40), and 35% (13/37) of the transplantations with
patients at risk in the 40-mg, 20-mg, and 10-mg alem-
tuzumab groups, respectively. At risk for CMV infec-
tion are seropositive patients, those whose donor is
seropositive, or when both are seropositive for CMV
before transplantation. Two patients in the 10-mg
group died of CMV indisease. EBV infection (positive
EBV-PCR) or disease (PTLD at any side) developed in
1 patient in the 40-mg group (3%), in 4 patients in the
20-mg group (8%), and in 2 patients in the 10-mg
group (4%). EBV pneumonia was the cause of death
in 2 patients (401 10-mg groups, 1 each). Adenoviral
and respiratoral syncytial viral infections were not
observed during the study period. After cessation of
their immunosuppression and the routinely used pro-
phylaxis, PjP was detected in 1 patient in the 10-mg
group and in 2 patients in the 20-mg group; one
patient experienced late toxoplasmosis retinitis
(10-mg group).
Response and Relapse
Eight patients died prior to response evaluation.
Of the remaining 119 patients evaluable for disease
response, 106 (84%) achieved CR at day 130.
Four patients achieved partial remission (PR; 4%),
1 patient had stable disease, and 8 patients were re-
fractory.
The cumulative incidence of relapse according to
Kaplan-Meier are 42% in the 40-mg group (11/30;
at median day 1104), 42% in the 20-mg group (18/
48; at median day1173) and 43% in the 10-mg group
(19/49; at median day1163), without statistical differ-
ence (Figure 4).NRM
The cumulative incidence of NRM at day1100, 1
year and 2 years revealed no differences among the 3
groups as the values were 10%, 20%, and 35% for
group 40 mg, 8%, 20%, and 20% for group 20 mg,
and 6%, 23%, and 26% for the 10-mg group
(Figure 5). Infections were the most common causes
of death. By groups, reasons for NRM were infection
(n57), central nervous system (CNS) toxicity (n51),
cardial (n51), aGVHD (n51), and cGVHD (n51) in
group 40 mg, infection (n55), CNS hemorrhage
(n52), primary solid tumor (n51), aGVHD (n51),
and multiorgan failure (MOF) (n52) in group 20
mg, and infection (n56), MOF (n53) and aGVHD
(n51) in group 10 mg (Figure 5).
Outcome (Table 3)
As of December 31, 2008, 62 patients are alive in
the 40-mg group 11/30 patients (37%; at median day
11673; range: 1274-1999), 23/48 patients in the
20-mg group (49%; at median day 11132; range:
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Figure 3. Kaplan-Meier estimated incidences of overall and extensive
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Figure 5. Kaplan-Meier estimated incidence of NRM.
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(57%; at median day 1759; range: 601-864). Kaplan-
Meier estimates for OS at day1100, 1 year, and 2 years
are 77%, 57%, and 50% for the 40-mg group, 90%,
69%, and 58% for the 20-mg group, and 91%, 61%,
and 57% in the 10-mg group, with no statistical differ-
ence either, respectively (Figure 6).Table 3. Outcome
40 mg
(n530)
20 mg
(n548)
10 mg
(n549)
CMV infection 10/26 (38%) 22/40 (55%) 13/37 (35%)
Best response
CR 21 40 46DISCUSSION
Alemtuzumab is increasingly being used as GVHD
prophylaxis in allogeneic RIC-HCT; however, the
optimal dose and timing have not been defined. Stud-
ies with large patients cohorts of patients have demon-
strated the efficacy of 100 mg alemtuzumab as part of
the conditioning to reduce GVHD incidence, yet with
a far greater incidence of severe viral infections and
relapse rates when compared to alemtuzumab-free
protocols [15]. Small studies with up to 20 patients
have shown that the alemtuzumab dose can be
reduced when combined with CsA/MTX treatment
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Figure 4. Kaplan-Meier estimated incidence of relapse.To our knowledge, ours is the first observational
study examing the deescalation of an alemtuzumab
dose still sufficient as GVHD prophylaxis in
RIC-HCT. We found low incidences of aGVHD
grade II-IV (7.5%-30%) and grade III-IV (7%-
11.5%) when 40 mg, 20 mg, or 10 mg, respectively,
of alemtuzumab was given 1 to 2 days prior to stem
cell infusion, and only 1 patient died of aGVHD.
Such low aGVHD rates have also been achieved with
100 mg alemtuzumab [18-21], and they compare fa-
vorably with protocols using standard CsA/MTX
GVHD prophylaxis in UD transplantation reducing
the incidence of aGVHD grade III-IV [22]. The
higher 30% incidence grade II-IV aGVHD in the
20-mg alemtuzumab group probably reflects the
higher rate of HLA-mismatches in that patient cohort
compared to the 40-mg group. It is striking that we ob-
served no significant difference in the degree of gradePR 2 1 1
Refractory 4 2 2
Stable disease 1
Not evaluable 3 4
Follow-up 31.12.08
Alive n5(%) 11 (37) 23 (49) 28 (57)
days in median
(range)
1673 (1274-1999) 1132 (950-1248) 759 (601-864)
Causes of death n519 n525 n521
Relapse/progress 9 14 11
GVHD acute/chronic 1/1 1/0 1/0
MOF/ARDS 1/1 2/1
Infection bact/fungal 6 5 3
CNS toxicity 1 2
CMV/EBV-infection 0/1 2/1
solid tumor 1
MOF indicates multiorgan failure; ARDS, acute respiratory distress syn-
drome; CNS, central nervous system; EBV, Epstein-Barr virus; CMV, cy-
tomegalovirus; PR, partial remission; CR, complete remission; GVHD,
graft-versus-host disease.
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Figure 6. Kaplan-Meier estimation for OS.
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alemtuzumab dose groups. Using low-dose alemtuzu-
mab (7.5 mg/m2 and 15 mg/m2) in a small trial with
sibling transplantation, Dodero et al. [23] also re-
ported a low incidences of aGVHD grade II-IV
(11%); however, their post-HCT immunsuppression
was more intensive than ours, because it consisted of
CsA and MTX.
Further, we did not observe significant differences
in overall (37%-44%) and extensive cGVHD (14%-
24%).These data compare favorably with overall
cGVHD of 11%-36% in other publications using
higher alemtuzmab doses [8,21,24]. However, we
observed no statistical differences in our patients for
the quality of life compromising extensive cGVHD
comparing the 3 groups. The low incidence of exten-
sive cGVHD in the low-dose groups (14% and 17%)
compares well with published data for higher doses
of alemtuzumab or low doses with additional immuno-
suppression [8,23].
With the 10-40-mg alemtuzumab doses used, we
observed only 1 graft failure in 1 particular patient
who underwent RIC-HCT in an accelerated phase of
her MPS. Such low incidences of graft failure have
also been shown in earlier trials with 50 mg alemtuzu-
mab in vivo [7]. In contrast, 100 mg alemtuzumab
doses given during RIC resulted in a significant rate
(3.5%-19%) of primary graft failure [18-21,25].
After alemtuzumab medication, patients are at risk
of acquiring viral infections (CMV, Epstein-Barr virus
[EBV], or Adenovirus) [9,15,26] or opportunistic in-
fections like PjP or toxoplasmosis [27] because of T
cell lymphocyte depletion. We found similar inci-
dences of CMV infection/reactivation in all dose
groups (35%-55%). Higher incidences as of 50% to
70% CMV reactivation have been reported after 100
mg alemtuzumab [15,20,
21,26,28,29] and up to 2% progressed to CMV-disease
despite preemptive therapy [15]. We observed 1 fatal
CMV pneumonia and 1 fatal CMV-colitis in addition
to aGVHD grade IV of the gut (10-mg group).Aggressive T cell depletion is also a risk factor for
EBV reactivation, disease, and potential PTLD devel-
opment [30]. We detected EBV infection/disease in 7
patients with no difference among the alemtuzumab
doses. Overall, 2 of them died of EBV pneumonia.
The PjP or toxoplasmosis infections occurred very
late, when the patients were off immunosuppression.
The occurrence of PjP or toxoplasmosis infection after
cessation of adequate prophylaxis with either TMS or
dapsone/daraprim after alemtuzumab GVHD pro-
phylaxis shows that patients must be examined for in-
dividual immunodeficiencies and prophylaxis should
be extended. Taken together, the low doses of alemtu-
zumab used in this study seem to be relatively safe
regarding opportunistic infections.
The low incidences of aGVHD and of severe, fatal
opportunistic infections are reflected in our low NRM.
Although our patients represented a high-risk popula-
tion for NRM (86% advanced disease and untreated,
average age 63 years, 66% UD, 21% mismatched
transplantations), day 1100 and 1-year NRM was
between 6% and 10% and 20% and 23% in the 3 alem-
tuzumab dose groups. Similarly, low incidences of
early (day1100) NRM have been observed in previous
studies with higher doses of alemtuzumab, in which an
NRM between 0% and 11% [7,21,24,31,32] and 14%
and 17% [19,20,26] was detected (mainly after first
allo-HCT from matched sibling donors).
As of December 31, 2008 we compared the OS in
all groups, with no apparent differences. Nor did we
detect any differences among the 3 alemtuzumab doses
when considering the cumulative incidence of relapse.
Our analysis on 3 cohorts of a total of 127 consec-
utive patients demonstrates that the deescalation of in
vivo alemtuzumab to 10 mg total dose given on day
21, combined with single agent CsA as posttransplan-
tation immunosuppression, results in adequate sup-
pression of aGVHD and extensive cGVHD without
elevating graft failures, viral infections, and early
relapse rates especially in sibling and UD allo-HCT.
We believe that the optimal therapeutic window of
alemtuzumab application in allogeneic HCT lies be-
tween a total dose of 10 mg and 20 mg, and that higher
doses do not seem necessary in HLA-matched trans-
plantations. Furthermore, the GVHD incidence seems
acceptable when 20-mg doses of alemtuzumab are ad-
ministered in HLA mismatched UD transplantations.
Low doses of alemtuzumab should also form the basis
for randomized trials when comparing the efficacy of
alemtuzumab versus standard GVHD prophylaxis
protocols such as CsA/MTX.ACKNOWLEDGMENTS
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